Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.31
- Piotroski Score 3.00
- Grade Overweight
- Symbol (ADPT)
- Company Adaptive Biotechnologies Corporation
- Price $4.66
- Changes Percentage (6.64%)
- Change $0.29
- Day Low $4.29
- Day High $4.70
- Year High $6.70
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $18.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.49
- Trailing P/E Ratio -2.42
- Forward P/E Ratio -2.42
- P/E Growth -2.42
- Net Income $-225,250,000
Income Statement
Quarterly
Annual
Latest News of ADPT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ...
The new gapfill price of $2,007 per test will positively impact long-term margins, with an expected increase in average selling price to $1,300 in 2025....
By Yahoo! Finance | 2 weeks ago -
Strong week for Adaptive Biotechnologies (NASDAQ:ADPT) shareholders doesn't alleviate pain of three-year loss
Adaptive Biotechnologies' stock price has shown a 72% increase in the last quarter, but a significant 88% drop over the past three years. Shareholders hope for sustained growth despite recent improvem...
By Yahoo! Finance | 3 months ago
